FRX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 16.20%

Insider Buying (Last 12 Months): C$157,867.93

Insider Selling (Last 12 Months): C$552,326.70

Fennec Pharmaceuticals Insider Trading History Chart

Fennec Pharmaceuticals Share Price & Price History

C^$7.08

+0.30 (1.20%)

As of 04/22/2025 01:00 AM ET

Days: 30 | 90 | 365

Fennec Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/11/2025	Chris Anigeron Rallis	Director	Sell	1,409	C$6.93	C$9,764.37
4/4/2025	Rostislav Christov Raykov	Director	Sell	10,000	C$7.46	C$74,550.00
3/5/2025	Rostislav Christov Raykov	Director	Sell	7,569	C$9.71	C$73,503.54
2/14/2025	Chris Anigeron Rallis	Director	Sell	1,186	C$9.68	C$11,485.70
2/5/2025	Rostislav Christov Raykov	Director	Sell	2,431	C$9.66	C$23,476.17
1/6/2025	Rostislav Christov Raykov	Director	Sell	10,000	C$8.76	C$87,552.00
12/20/2024	Rostislav Christov Raykov	Director	Buy	25,000	C$3.87	C$96,840.00
12/5/2024	Rostislav Christov Raykov	Director	Buy	796	C$8.52	C$6,779.05
11/18/2024	Robert Christopher Andrade	Senior Officer	Buy	15,816	C$3.43	C$54,248.88
10/8/2024	Chris Anigeron Rallis	Director	Sell	1,406	C$6.16	C$8,662.08
10/2/2024	Rostislav Christov Raykov	Director	Sell	2,431	C$6.67	C$16,212.34
9/4/2024	Rostislav Christov Raykov	Director	Sell	2,431	C$7.45	C$18,115.81
7/5/2024	Chris Anigeron Rallis	Director	Sell	1,173	C$6.03	C$7,073.19
7/1/2024	Rostislav Christov Raykov	Director	Sell	2,431	C$6.13	C$14,902.03
4/23/2024	Adrian J. Haigh	Senior Officer	Sell	22,223	C$9.32	C$207,029.47
4/15/2024	Adrian J. Haigh	Senior Officer	Buy	22,222	C$2.31	C$51,332.82
4/15/2024	Chris Anigeron Rallis	Director	Sell	800	C$10.45	C$8,360.00
3/26/2024	Chris Anigeron Rallis	Director	Sell	2,114	C$10.97	C$23,190.58
3/26/2024	Robert Christopher Andrade	Senior Officer	Sell	13,975	C$10.90	C$152,345.67
11/24/2023	Chris Anigeron Rallis	Director	Sell	269	C$8.25	C$2,219.25
11/16/2023	Khalid Islam	Director	Buy	20,492	C$2.44	C$50,000.48
11/3/2023	Rostislav Christov Raykov	Director	Buy	74,793	C$1.59	C$118,920.87
4/28/2023	Chris Anigeron Rallis	Director	Sell	916	C$8.34	C$7,639.44
11/17/2022	Chris Anigeron Rallis	Director	Sell	333	C$10.63	C$3,538.69	30,018
10/20/2022	Chris Anigeron Rallis	Director	Sell	2,068	C$10.66	C$22,035.37	25,589
9/21/2022	Robert Christopher Andrade	Senior Officer	Sell	19,052	C$11.02	C$209,888.26	176,721
9/12/2022	Rostislav Christov Raykov	Director	Sell	16,666	C$0.93	C$15,479.38	21,081,996
7/18/2022	Chris Anigeron Rallis	Director	Buy	11,111	C$0.59	C$6,499.94	32,036

See Full Table

SEC Filings (Institutional Ownership Changes) for Fennec Pharmaceuticals (TSE:FRX)

52.78% of Fennec Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Today's Range

Now: C$7.08

C$7.08

50 Day Range

MA: C$8.73

C$7.02

C$10.14

52 Week Range

Now: C$7.08

C$5.65

C$13.72

Volume

N/A

Average Volume

1,319 shs

Market Capitalization

C$136.54 million

P/E Ratio

N/A

Dividend Yield

2.02%

Beta

0.25

Who are the company insiders with the largest holdings of Fennec Pharmaceuticals?: Fennec Pharmaceuticals' top insider shareholders include:
Adrian J Haigh (Senior Officer)
Chris Anigeron Rallis (Director)
Khalid Islam (Director)
Robert Christopher Andrade (Senior Officer)
Rostislav Christov Raykov (Director)
Learn More about top insider investors at Fennec Pharmaceuticals.